Treating and Diagnosing Rare Cancers in Young Adults
Robert Chen, MD, and Hodgkin’s lymphoma patient, Jeremy Hernandez, speak on the challenges of receiving and treating a rare cancer diagnosis in young adults.
Advancing Treatment for Myelodysplastic Syndrome Through Collaboration
A team of investigators has found that collaborative efforts among several leading medical institutions have helped increase the study of new medications for myelodysplastic syndromes (MDS).
Using Interferon‐α2 & Ruxolitinib Combination Therapy to Treat Myeloproliferative Neoplasms
Interferon‐α2 and ruxolitinib combination therapy shows promise in treating myeloproliferative neoplasms, according to recent preliminary findings.
Rare Tumor Patient Engagement Network: Getting Patients Involved in Cancer Research
Karlyne Reilly, PhD, discusses the Rare Tumor Patient Engagement Network and the importance of getting patients with rare conditions involved in cancer research.
Priority Review Granted to Combination Therapy for Previously Untreated Subsets of Leukemia & Lymphoma
The FDA has granted a priority review to combination therapy, ibrutinib/obinutuzumab, for the treatment of previously untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
Fibrolamellar Cancer Foundation President on What's Next For Rare Cancers
John Hopper, MBA, highlights advances made in the fight against rare cancers and discusses what’s next for the community.
Advances Made in Cancer Treatment, but Questions Remain
Although there have been many successes experienced in the oncology community, more genomic data is needed.
Glioblastoma Treatment, MN-166, Granted Orphan Drug Designation
The FDA has granted an orphan drug designation to MediciNova Inc.’s MN-166, an adjunctive therapy to temozolomide treatment for patients with glioblastoma.
Top 5 Rare Disease News of the Week—September 23, 2018
Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.
Robert J. Kreitman, MD, on New Kind of Treatment for Hairy Cell Leukemia
Robert J. Kreitman, MD, discusses the FDA’s recent approval of moxetumomab
pasudotox (Lumoxiti) for the treatment of hairy cell leukemia (HCL).
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.